208 related articles for article (PubMed ID: 11896093)
41. Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA).
Corte MD; Rodil JA; Vázquez J; García L; Rodríguez JC; Bongera M; Fernández JC; González LO; Lamelas ML; Allende M; García-Muñiz JL; Fueyo A; Vizoso FJ
J Cancer Res Clin Oncol; 2005 Nov; 131(11):701-14. PubMed ID: 16075281
[TBL] [Abstract][Full Text] [Related]
42. Serum HER-2/neu in the management of breast cancer patients.
Lüftner D; Lüke C; Possinger K
Clin Biochem; 2003 Jun; 36(4):233-40. PubMed ID: 12810150
[TBL] [Abstract][Full Text] [Related]
43. Breast cancer: what's HER-2/neu got to do with it?
Lenahan C; Dennis C; Isakovich NV; Pories SE
Curr Surg; 2005; 62(5):459-64. PubMed ID: 16125599
[No Abstract] [Full Text] [Related]
44. Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play?
Prowell TM; Armstrong DK
Semin Oncol; 2006 Dec; 33(6):681-7. PubMed ID: 17145348
[TBL] [Abstract][Full Text] [Related]
45. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
Konecny GE; Thomssen C; Lück HJ; Untch M; Wang HJ; Kuhn W; Eidtmann H; du Bois A; Olbricht S; Steinfeld D; Möbus V; von Minckwitz G; Dandekar S; Ramos L; Pauletti G; Pegram MD; Jänicke F; Slamon DJ
J Natl Cancer Inst; 2004 Aug; 96(15):1141-51. PubMed ID: 15292386
[TBL] [Abstract][Full Text] [Related]
46. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
[TBL] [Abstract][Full Text] [Related]
47. The prognostic and predictive values of ECD-HER-2.
Hait WN
Clin Cancer Res; 2001 Sep; 7(9):2601-4. PubMed ID: 11555568
[TBL] [Abstract][Full Text] [Related]
48. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.
Köstler WJ; Schwab B; Singer CF; Neumann R; Rücklinger E; Brodowicz T; Tomek S; Niedermayr M; Hejna M; Steger GG; Krainer M; Wiltschke C; Zielinski CC
Clin Cancer Res; 2004 Mar; 10(5):1618-24. PubMed ID: 15014012
[TBL] [Abstract][Full Text] [Related]
49. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
50. Study of the measurement of serum extracellular domain of HER-2/neu protein with CLIA method.
Kuroda N; Kontani K; Kajikawa T; Taminato T
Rinsho Byori; 2010 Jun; 58(6):541-52. PubMed ID: 20662264
[TBL] [Abstract][Full Text] [Related]
51. Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer.
James R; Thriveni K; Krishnamoorthy L; Deshmane V; Bapsy PP; Ramaswamy G
Indian J Med Res; 2011 Jan; 133(1):70-5. PubMed ID: 21321422
[TBL] [Abstract][Full Text] [Related]
52. Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
Im SA; Kim SB; Lee MH; Im YH; Lee KH; Song HS; Lee MA; Lee J; Lee NS; Ham HS; Kim TY; Park YH; Lee KE; Kim KW; Seo JH; Lee SN; Hong YS; Bang YJ; Kim WK; Park HS
Oncol Rep; 2005 Aug; 14(2):481-7. PubMed ID: 16012734
[TBL] [Abstract][Full Text] [Related]
53. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
[TBL] [Abstract][Full Text] [Related]
54. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
Russell CA; Green SJ; O'Sullivan J; Hynes HE; Budd GT; Congdon JE; Martino S; Osborne CK
J Clin Oncol; 1997 Jul; 15(7):2494-501. PubMed ID: 9215817
[TBL] [Abstract][Full Text] [Related]
55. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
[TBL] [Abstract][Full Text] [Related]
56. Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.
Bewick M; Chadderton T; Conlon M; Lafrenie R; Morris D; Stewart D; Glück S
Bone Marrow Transplant; 1999 Aug; 24(4):377-84. PubMed ID: 10467326
[TBL] [Abstract][Full Text] [Related]
57. Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients.
Thriveni K; Deshmane V; Bapsy PP; Krishnamoorthy L; Ramaswamy G
Indian J Med Res; 2007 Feb; 125(2):137-42. PubMed ID: 17431282
[TBL] [Abstract][Full Text] [Related]
58. HER-2/neu gene product in serum--an oncoprotein in the diagnosis and therapy of breast carcinoma.
Schulze G
Anticancer Res; 2003; 23(2A):1007-10. PubMed ID: 12820339
[TBL] [Abstract][Full Text] [Related]
59. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.
Kim YS; Konoplev SN; Montemurro F; Hoy E; Smith TL; Rondón G; Champlin RE; Sahin AA; Ueno NT
Clin Cancer Res; 2001 Dec; 7(12):4008-12. PubMed ID: 11751494
[TBL] [Abstract][Full Text] [Related]
60. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
